The global premature ejaculation therapeutics market was valued at USD 2.45 billion in 2023 and is expected to reach USD 4.06 billion by 2029, growing at a CAGR of 8.74% during the forecast period. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally. Considering the high prevalence of the disease, vendors, government organizations, and healthcare professionals are focusing on increasing awareness about the disease and trying to widen the reach of PE therapeutics through multiple distribution channels. Moreover, the high prevalence of premature ejaculation is driving many market players to develop innovative drug formulations for the management of premature ejaculation, which is contributing to the premature ejaculation therapeutics market growth. Also, constant product development and advanced drug formulations with minimal side effects are keys to achieving high sales growth. Product diversification plays a vital role in strengthening the market position of key vendors.
WHY THIS REPORT?
This report provides
- A thorough insight into the structure and size of each industry segment.
- An Analysis of several micro-market indicators considering growth factors, market prospects, and strategic contribution to the industry.
- Overviews of top manufacturers/marketed products, pipeline analysis, clinical trial analysis, competitive landscape, vendor profiles, mergers & acquisitions.
- Provide strategic planning, such as comprehensively understanding consumer behavior, competitors, new product development, geographic market expansion, and merger & acquisition pipelines.
- Insights to formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing various competitors' performance.
- Identifies emerging players with potentially strong product portfolios and creates effective counter strategies to gain a competitive advantage.
MARKET TRENDS & DRIVERS
Advancements in PE Drug Formulation Technology
With the application of nanotechnology, researchers have explored new approaches to medicine delivery to promote efficacy and minimize the side effects of the currently available agents for premature ejaculation. Pharmaceutical advancements improve the effectiveness and safety of drugs by enhancing bioavailability, improving drug absorption, and modifying the drug release rate. Drug formulation of PE drugs has experienced advancements in recent years. For instance, PE drugs such as Absorption Pharmaceuticals' Promescent and Plethora Solutions' Fortacin are formulated as topical eutectic liquid sprays. Rapid advancements will drive the premature ejaculation therapeutics market growth during the forecast period.
Wide Accessibility of OTC Drugs and & General Off-label Drugs for PE
Most of the drugs prescribed for treating PE are off-label. The availability of low-cost generics of off-label PE drugs such as sildenafil, tadalafil, and vardenafil and the high accessibility of OTC PE drugs through physical drug stores, specialty health stores, and e-pharmacies are contributing majorly to the increased uptake of therapeutic medicines over other alternative methods for treating PE.
High Demand for Topical Drug Therapies to Treat PE
Topical therapies that are commonly used result in prolonged intravaginal ejaculatory latency time at the expense of potential penile/vaginal hypotheses. A topical lidocaine-prilocaine-containing spray (FORTACIN) has been developed, with initial results demonstrating a 6.3-fold increase in the intravaginal ejaculatory latency time and an associated improvement in patient-reported outcome measures of control and sexual satisfaction. Almost all topical PE drugs are available as OTC drugs that consumers can purchase without a physician’s prescription. Topical drugs are mainly amide anesthetics, which comprise lidocaine, benzocaine, or a combination of lidocaine and prilocaine. They offer improved ease of use and are associated with minimal/no systemic adverse events. Such improved drug therapies are likely to drive the future growth of the global premature ejaculation therapeutics market.
INSIGHTS BY DRUG CLASS
The global premature ejaculation therapeutics market by drug class is segmented into Selective Serotonin Re-uptake Inhibitors (SSRIs), Phosphodiesterase type 5 (PDE5) Inhibitors, anesthetic agents, and others. The Selective Serotonin Re-uptake Inhibitors (SSRIs) segment accounted for the largest industry share and is anticipated to retain its market dominance during the forecast period. SSRIs are considered effective drugs for treating PE, and they majorly include sertraline, paroxetine, fluoxetine, escitalopram, citalopram, and dapoxetine. Among these, dapoxetine (Priligy) is the only licensed drug for treating PE in New Zealand, Sweden, Austria, Finland, Germany, Spain, Italy, and Portugal. Apart from Priligy, all other SSRIs that are recommended for the treatment of PE are used as off-label medications. Further, through multiple evidence-based clinical studies, the satisfactory efficacy and safety of SSRIs in delaying ejaculation have been demonstrated. Thus, despite the regulatory authority approval, the off-label use of SSRIs in the management of PE is currently recommended by the AUA guidelines, the updated second ISSN guidelines, and many others.
INSIGHTS BY ROUTE OF ADMINISTRATION
The oral PE therapeutics market segment was the major revenue contributor in 2023, as physicians majorly prescribe oral therapeutics for treating PE; the oral PE therapeutics segment is the major revenue contributor to the global premature ejaculation therapeutics market. Although the number of oral medications recommended or used for the treatment of PE is high, all these drugs (except Priligy) are off-label. Oral therapeutics may be administered either daily or on-demand before sexual intercourse. Further, the growing PE prevalent population and increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment of the global premature ejaculation therapeutics market. Generic versions are approved for almost all off-label drugs recommended for the treatment of PE, such as Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro. Also, the availability of low-cost generic drugs has significantly increased the uptake of oral PE drugs for the management of PE in both developed and developing countries.
INSIGHTS BY AGE GROUP
The below 45 Years age group dominated the global premature ejaculation therapeutics market share in 2023. The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the industry growth during the forecast period. Moreover, changes in lifestyles, smoking, and consumption of alcohol are a few significant factors contributing to the rising disease pool.
North America was the largest geographical segment of the global premature ejaculation therapeutics market in 2022, with a share of over 43%. The presence of a large proportion of the PE population, coupled with better access to PE, especially OTC drugs, is the primary factor for its high industry share. Moreover, the region's disease prevalence will likely increase during the forecast period. The increased stressful lifestyle and rise in chronic conditions like diabetes and prostate cancer can lead to the incidence of PE. Also, an increased incidence of cancers, especially prostate cancer, is likely to contribute to higher PE prevalence during the forecast period.
Further, the U.S. accounted for a significant share of the North American premature ejaculation therapeutics market in 2023. The country holds the highest market value due to better healthcare accessibility, coverage, and spending. The demand for PE treatment in the country is increasing at a healthy rate owing to the significant rise in prevalence/incidence of premature ejaculation in adult men. According to the National Health and Social Life Survey (NHSLS), an estimated 60%-70% of males in the U.S. experience some form of premature ejaculation. The organization estimated that the country has a prevalence rate of 30%, increasing steadily among all the young and adult age groups.
The European region holds a significant share of the global premature ejaculation therapeutics market, is growing at a healthy rate, and is expected to grow at a similar pace during the forecast period. Europe, particularly Western Europe, has a sophisticated and established healthcare infrastructure, and people have access to advanced healthcare services, including treatment for male sexual dysfunction like premature ejaculation. The significant share of the region in the global premature ejaculation therapeutics market is mainly due to the high prevalence of PE disorders, the presence of major and emerging vendors either marketing or distributing PE drugs, and wide access to multiple off-label and OTC PE drug formulations. Further, the prevalence of PE across European countries is likely to rise during the forecast period, which, in turn, is expected to contribute to increasing the PE treatment pool, thereby driving the size of the PE industry. The growing prevalence of diseases that are associated with the risk of PE incidence as a co-morbid condition and the rise in acute and chronic stress will drive the PE prevalence population.
The global premature ejaculation therapeutics market is relatively fragmented and characterized by pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors offer off-label drugs, generic versions, and OTC topical anesthetic agents. Drugs offered by global players in the global premature ejaculation therapeutics market, such as Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline, are used as off-label drugs for treating PE. Therefore, these international players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan, are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs for treating PE. In recent years, the global premature ejaculation therapeutics market has witnessed many strategic initiatives by key vendors, intensifying market competitiveness. In 2014, Royalty Pharma acquired the rights of Priligy from Allergan to expand its product portfolio and establish its presence in the premature ejaculation therapeutics market.